News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Lonza CEO Quits As Profit Tumbles, Shares Drop
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Lonza (LONN.VX: Quote, Profile, Research) Chief Executive Markus Gemuend quit on Tuesday as the specialty chemicals maker posted a dire 59 percent drop in 2003 profit, hit by oversupply in the biotechnology market.
Twitter
LinkedIn
Facebook
Email
Print
People
Lonza
MORE ON THIS TOPIC
Earnings
Merck Bats Away ‘Modest Growth’ Accusations, Touts Broad Pipeline
February 3, 2026
·
2 min read
·
Dan Samorodnitsky
Layoff Tracker
GSK Puts up to 350 US, UK Jobs on the Chopping Block
February 3, 2026
·
49 min read
·
BioSpace Editorial Staff
Rare diseases
GSK Hands RNA Editor Back to Wave After Underwhelming Early AATD Data
February 2, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Eli Lilly Commits $3.5B To Build Injectable Obesity Drug Plant in PA
February 2, 2026
·
2 min read
·
Nick Paul Taylor
